
InflaRx (IFRX) Stock Forecast & Price Target
InflaRx (IFRX) Analyst Ratings
Bulls say
InflaRx NV is a clinical-stage biopharmaceutical company developing vilobelimab, a first-in-class anti-C5a monoclonal antibody that has shown a significant reduction in all-cause mortality by 23.9% within 28 days of treatment. The therapy has also demonstrated the potential to lower corticosteroid use, promoting corticosteroid-free treatment options for patients with autoimmune vasculitis (AAV). These promising clinical results underscore the potential market opportunity for vilobelimab in managing inflammatory diseases, signaling a positive outlook for the company's stock.
Bears say
InflaRx NV is facing a negative outlook largely due to its depressed forward multiples, which are attributed to ongoing market volatility. The company's cash burn is uncertain and could be significantly influenced by the developmental stage of its programs, as well as by potential revenue influx from partnerships or collaborations. Additionally, the commercial sales of GOHIBIC are not currently valued, as the asset is not considered to be in a growth stage, with projected revenue generation remaining stagnant.
This aggregate rating is based on analysts' research of InflaRx and is not a guaranteed prediction by Public.com or investment advice.
InflaRx (IFRX) Analyst Forecast & Price Prediction
Start investing in InflaRx (IFRX)
Order type
Buy in
Order amount
Est. shares
0 shares